- Home
- CACC vs LEGN Comparison
CACC vs LEGN Comparison
Compare CACC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CACC
- LEGN
- Stock Information
- Founded
- CACC 1972
- LEGN 2014
- Country
- CACC United States
- LEGN United States
- Employees
- CACC N/A
- LEGN N/A
- Industry
- CACC Finance: Consumer Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CACC Finance
- LEGN Health Care
- Exchange
- CACC Nasdaq
- LEGN Nasdaq
- Market Cap
- CACC 6.3B
- LEGN 5.4B
- IPO Year
- CACC 1992
- LEGN 2020
- Fundamental
- Price
- CACC $522.61
- LEGN $36.08
- Analyst Decision
- CACC Sell
- LEGN Strong Buy
- Analyst Count
- CACC 2
- LEGN 12
- Target Price
- CACC $475.00
- LEGN $73.36
- AVG Volume (30 Days)
- CACC 106.6K
- LEGN 1.0M
- Earning Date
- CACC 10-29-2025
- LEGN 08-11-2025
- Dividend Yield
- CACC N/A
- LEGN N/A
- EPS Growth
- CACC 143.69
- LEGN N/A
- EPS
- CACC 34.75
- LEGN N/A
- Revenue
- CACC $1,173,200,000.00
- LEGN $796,838,000.00
- Revenue This Year
- CACC $157.70
- LEGN $70.75
- Revenue Next Year
- CACC $3.60
- LEGN $52.47
- P/E Ratio
- CACC $15.04
- LEGN N/A
- Revenue Growth
- CACC 43.92
- LEGN 74.75
- 52 Week Low
- CACC $409.22
- LEGN $27.34
- 52 Week High
- CACC $560.00
- LEGN $57.54
- Technical
- Relative Strength Index (RSI)
- CACC 63.00
- LEGN 48.36
- Support Level
- CACC $501.11
- LEGN $34.14
- Resistance Level
- CACC $523.90
- LEGN $36.17
- Average True Range (ATR)
- CACC 13.24
- LEGN 1.08
- MACD
- CACC 3.98
- LEGN 0.07
- Stochastic Oscillator
- CACC 86.11
- LEGN 48.67
About CACC Credit Acceptance Corporation
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.